Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNIPE: Nivolumab plus Lenvatinib for Advanced Biliary Tract Cancer
jRCT2091220436Phase 2Completed
- Sponsor
- National Cancer Center Hospital
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and lenvatinib in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer and 1 more, sponsored by National Cancer Center Hospital. Started Aug 2019; status: completed.
02
Drugs
nivolumablenvatinib
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on jRCT2091220436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220436.